• AEterna Zentaris has initiated a European multicenter Phase II trial of perifosine, a novel, first-in-class, oral signal transduction inhibitor, in combination with radiotherapy, in non-small cell lung cancer.
• CytRx Corp. has announced that the FDA has granted "fast-track" designation for the company’s leading drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis.
• CuraGen Corp. and TopoTarget A/S have announced the initiation of patient dosing in a Phase Ib open-label, multicenter, proof-of-concept clinical trial evaluating PXD101, a small molecule histone deacetylase inhibitor, for the treatment of advanced solid tumors, including colorectal cancer.
• CuraGen Corp. expects to complete the enrollment of patients in its Phase II randomized, double-blind, placebo-controlled clinical trial evaluating a single dose of velafermin (CG53135) for the prevention of oral mucositis in cancer patients undergoing bone marrow transplantation.
• ChemGenex Pharmaceuticals Limited has launched a new Phase II study evaluating the use of sHHT (Ceflatonin) in patients with accelerated-phase chronic myeloid leukemia who are resistant to the first-line therapy imatinib mesylate (Gleevec).
• Coley Pharmaceutical Group has initiated a five-arm Phase Ib clinical study of CPG 10101 (Actilon) alone and in combination with the current standard of care for the treatment of chronic hepatitis C virus.
• XTL Biopharmaceuticals Ltd. has initiated the Phase 1a clinical trial of XTL-6865 for the treatment of hepatitis C virus.
• ActivBiotics has announced plans to pursue a Phase II trial of its lead product, rifalazil, as a novel medical treatment for peripheral arterial disease.
• Koronis Pharmaceuticals has initiated a Phase 1b clinical trial of KP-1461, its novel anti-viral therapeutic, in HIV-positive patients.
• Alpharma has received clearance from the FDA to advance into a Phase II multidose clinical efficacy trial for an abuse-resistant, extended-release opioid. This product is being developed by the company for the treatment of chronic moderate-to-severe malignant (cancer-related) and non-malignant pain.
• Vion Pharmaceuticals has received fast track designation from the FDA for its anticancer agent VNP40101M (cloretazine) for induction treatment of patients older than 60 years of age with poor-risk acute myelogenous leukemia.
• Millennium Pharmaceuticals has initiated a Phase I/II, open-label, multicenter study of MLN518 in combination with standard induction chemotherapy in patients with newly diagnosed acute myelogenous leukemia.
• Schering-Plough Corp. has discontinued a Phase II study with its investigational CCR5 receptor antagonist, vicriviroc, used in combination with lamivudine/zidovudine (Combivir) in treatment-naive HIV patients. This decision was due to a return of detectable virus in some patients late in therapy compared to the control regimen of lamivudine/zidovudine and efavirenz (Sustiva), a current standard of care for treatment-naive patients living with HIV.
• Centocor and Eli Lilly & Co. have announced that patient enrollment in the Phase III trial of abciximab (Reopro) for the treatment of acute ischemic stroke has been permanently discontinued.
AEterna Zentaris has initiated a European multicenter Phase II trial of perifosine, a novel, first-in-class, oral signal transduction inhibitor, in combination with radiotherapy, in non-small cell lung cancer.You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content